The FDA has approved upadacitinib 15 mg once daily (Rinvoq, AbbVie) as an oral therapy for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
This additional indication follows the FDA approval of the drug this year for adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more TNF